A Pilot Study of Denileukin Diftitox in Combination With High-Dose IL-2 for Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase 0
Latest Information Update: 17 Aug 2012
At a glance
- Drugs Aldesleukin (Primary) ; Denileukin diftitox (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 May 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.